IQVIA HoldingsNYSE: IQV

The growth in IQV's revenue during the third quarter of 2024 is supported by strong performance in the Research and Development, as well as the Technology and Analytics areas.

IQVIA Holdings (IQV) reported quarterly earnings of $2.84 per share, which is higher than the Zacks Consensus Estimate of $2.81 per share. This is an increase compared to earnings of $2.49 per share from the same period last year.

On Thursday, the contract research company IQVIA reduced its yearly revenue predictions because two clinical trials have been delayed, as one of its clients is experiencing logistical issues.

IQV's revenues from TAS and RD&S are expected to rise, while CSMS revenues are probably going to decrease in the third quarter of 2024.

IQV enjoys advantages from being a market leader, its focus on data-driven innovation, and its growth around the world. However, it also faces challenges related to pricing pressures.

IQVIA has a large database and specialized IT systems for healthcare, along with data analysis advancements, which help it expand in the $300 billion market.

RBC Capital Markets has started to analyze IQVIA Holdings Inc. (IQV), highlighting that the company's main advantage is its valuable data resources. The analyst points out that IQVIA is the largest contract research organization in the world.

On September 4, 2024, in Philadelphia, Signant Health, a top company in evidence generation for contemporary clinical trials, revealed that it has partnered with IQVIA. IQVIA is a prominent global provider of advanced analytics, technology solutions, and clinical research services for the life sciences sector. Together, they are working on the One Home for Sites™ initiative.

IQVIA (IQV) shared its earnings report 30 days ago. What can we expect for the stock moving forward?